Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats

Japanese Journal of Pharmacology

Volumn 73, Issue 2, 1997, Pages 133-144

  Ashizawa, Naoki ^a   Yoshida, Motoyuki ^a   Sugiyama, Yoshiko ^a   Akaike, Nobuhide ^a   Ohbayashi, Shigeo ^a   Aotsuka, Tomoji ^a   Abe, Naoki ^a   Fukushima, Kanako ^a   Matsuura, Akihiro ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

Author keywords

Aldose reductase inhibitor; Cataract formation; Diabetic neuropathy; Motor nerve conduction velocity; Sorbitol

Indexed keywords

3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; GLYCERALDEHYDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SG 210; SORBITOL; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CATARACTOGENESIS; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; LENS; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RETINA; SCIATIC NERVE; STREPTOZOCIN DIABETES;

EID: 0030996652     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.73.133     Document Type: Article

References (37)

1. Hayman S and Kinoshita JH: Isolation and properties of lens aldose reductase. J Biol Chem 240, 877-882 (1965)
2. Gabbay KH: The sorbitol pathway and the complications of diabetes. N Engl J Med 288, 831-836 (1973)
3. Ghahary A, Luo JM, Gong YW, Chakrabarti S, Sima AA and Murply LJ: Increased renal aldose reductase activity, immunoreactivity and mRNA in streptozotocin-induced diabetic rats. Diabetes 38, 1067-1071 (1989)
4. Gabbay KH, Merola LO and Field RA: Sorbitol pathway: Presence in nerve and cord with substrate accumulation in diabetes. Science 151, 209-210 (1966)
5. Heyningen RV: Formation of polyols by the lens of the rat with 'sugar' cataract. Nature 184, 194-195 (1959)
6. Varma SD, Schocket SS and Richards RD: Implications of aldose reductase in cataracts in human diabetes. Invest Ophthalmol Vis Sci 18, 237-241 (1979)
7. Akagi Y, Kador PF, Kuwabara T and Kinoshita JH: Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 24, 1516-1519 (1983)
8. Schofield PJ and Could NJ: Initial changes in the free carbohydrate profile of rat lens and retina following streptozotocin-induced diabetes. Mol Cell Biochem 28, 17-21 (1979)
9. Engerman RL and Kern TS: Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33, 97-100 (1984)
10. Cohen MP: Aldose reductase, glomerular metabolism, and diabetic neuropathy. Metabolism 35, Supp 1, 55-59 (1986)
11. Beyer-Mears A: The polyol pathway, Sorbinil and renal dysfunction. Metabolism 35, Supp 1, 46-54 (1986)
12. +. Kidney Int 41, 778-788 (1992)
13. Geisen K, Utz R, Grotsch H, Lang HJ and Nimmesgern H: Sorbitol-accumulating pyrimidine derivatives. Arzneimittelforschung 44, 1032-1043 (1994)
14. Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I and Shigeta Y: Effect of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther 229, 226-230 (1984)
15. Simard-Duquesne N, Greselin E, Dubuc J and Dvornik D: The effect of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats. Metabolism 34, 885-892 (1985)
16. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, Ohkubo Y, Notsu Y and Yamaguchi I: Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism 40, 77-87 (1991)
17. Matsui T, Nakamura Y, Ishikawa H, Matsuura A and Kobayashi F: Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol 64, 115-124 (1994)
18. Mizuno K, Kato N, Matsubara A, Nakano K and Kurono M: Effects of a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]- 2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 41, 1081-1086 (1992)
19. Clements RS Jr and Winegrad AI: Purification of alditol: NADP oxidoreductase from human placenta. Biol Biophys Res Commun 47, 1473-1479 (1972)
20. VanderJagt DL, Hunsaker LA, Robinson B, Stangebye LA and Deck LM: Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. J Biol Chem 265, 10912-10918 (1990)
21. Bhatnagar A, Liu S, Das B, Ansari NH and Srivastava SK: Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. Biochem Pharmacol 39, 1115-1124 (1990)
22. Bergmeyer HU, Gruber W and Gutmann I: D-Sorbitol. In Methods of Enzymatic Analysis (second edition), Edited by Bergmeyer HU, Vol 3, pp 1323-1330, Academic Press, Inc, New York (1974)
23. Miyoshi T and Goto I: Serial in vivo determinations of nerve conduction velocity in rat tails. Physiological and pathological changes. Electroencephalogr Clin Neurophysiol 35, 125-131 (1973)
24. Ao S, Kikuchi C, Ono T and Notsu Y: Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract. Invest Ophthalmol Vis Sci 32, 3078-3083 (1991)
25. Kador PF, Akagi Y and Kinoshita JH: The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism 35, Supp 1, 15-19 (1986)
26. Chylack LT, Leske MC, Sperduto R, Khu P, McCarthy D and the Lens Opacities Case-Control Study Group: Lens opacities classification system. Arch Ophthalmol 106, 330-334 (1988)
27. Tao RV, Takahashi Y and Kador PF: Effect of aldose reductase inhibitors on naphthalene cataract formation in the rat. Invest Ophthalmol Vis Sci 32, 1630-1637 (1991)
28. Yamamoto Y and Ohtori A: In vitro study of aldose reductase inhibitor concentrations in the lens and inhibitory effect on sugar alcohol accumulation. Curr Eye Res 9, 421-428 (1990)
29. Ohtori A, Yamamoto Y and Tojo KJ: Penetration and binding of aldose-reductase inhibitors in the lens. Invest Ophthalmol Vis Sci 32, 189-193 (1991)
30. Inukai S, Agata M, Sato M, Naitou A, Matsukawa H and Goto M: Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats. Jpn J Pharmacol 61, 221-227 (1993)
31. Yasuda H, Sonobe M, Yamashita M, Terada M, Hatanaka I, Huitian Z and Shigeta Y: Effect of prostaglandin E1 analogue TFC612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes 38, 832-838 (1989)
32. Shindo H, Tawata M, Aida K and Onaya T: The role of a cyclic adenosine 3′,5′-monophosphate and polyol metabolism in diabetic neuropathy. J Clin Endocrinol Metab 74, 393-398 (1992)
33. Beyer-Mears A and Cruz E: Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. Diabetes 34, 15-21 (1985)
34. Hu TS, Datiles M and Kinoshita JH: Reversal of galactose cataract with Sorbinil in rats. Invest Ophthalmol Vis Sci 24, 640-644 (1983)
35. Kinoshita JH: Mechanisms initiating cataract formation. Invert Ophthalmol 13, 713-723 (1974)
36. Win T, Asano G and Shimizu Y: The efficacy of aldose reductase inhibitor, antioxidant butylated hydroxytoluene and cysteine protease inhibitor E64 on hyperglycemia-induced metabolic changes in the organ-cultured bovine lens. J Nippon Med Sch 61, 180-189 (1994)
37. Azuma M, Inoue E, Oka T and Shearer TR: Proteolysis by calpain is an underlying mechanism for formation of sugar cataract in rat lens. Curr Eye Res 14, 27-34 (1995)